

RESEARCH ARTICLE OPEN ACCESS

Patterns of Postmastectomy Radiotherapy in Immediate Breast Reconstruction—Results From the iBRA-2 Cohort Study

Tim Rattay¹ | Adam Trickey² | Rachel L. O'Connell³ | Rajiv V. Dave⁴ | Joanna Skillman⁵ | Nicola L. P. Barnes⁴ | Matthew D. Gardiner^{6,7} | Chris Holcombe⁸ | Shelley Potter^{2,9}

¹Leicester Cancer Research Centre, University of Leicester, Leicester, UK | ²Population Health Sciences, University of Bristol, Bristol, UK | ³Department of Breast Surgery, The Royal Marsden NHS Foundation Trust, Sutton, UK | ⁴Nightingale Breast Unit, Manchester University NHS Foundation Trust, Manchester, UK | ⁵Department of Plastic Surgery, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK | ⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK | ⁷Department of Plastic Surgery, Wexham Park Hospital, Slough, UK | ⁸Swansea Bay University Health Board, Swansea, UK | ⁹Bristol Breast Care Centre, North Bristol NHS Trust, Bristol, UK

Correspondence: Tim Rattay (tr104@le.ac.uk)

Received: 7 October 2025 | **Revised:** 1 March 2026 | **Accepted:** 13 March 2026

Academic Editor: Ivana Ribeiro

Keywords: breast cancer | cohort study | immediate breast reconstruction | radiotherapy | trainee collaborative

ABSTRACT

Purpose: Long-term data indicate that postmastectomy radiotherapy (PMRT) is associated with improved overall survival in node-positive breast cancer patients. Immediate breast reconstruction (IBR) remains controversial in the context of planned PMRT, but rates of IBR are increasing. The aim of this study was to examine patterns of PMRT in patients undergoing mastectomy with or without IBR.

Methods: Data were collected from 2526 patients enrolled in the iBRA-2 prospective cohort study undergoing 2606 mastectomies with and without IBR between 1 July 2016 and 31 December 2016. Patients were recruited consecutively at 71 centres across the United Kingdom (UK) and Ireland and at five international centres. Univariable and multivariable logistic regression models were used to explore associations between recommendation for PMRT and patient- and procedure-related factors.

Results: Of 2590 breast procedures included in the analysis, 696 were implant-based, 105 pedicled-flap and 230 free-flap reconstructions, and 32.5% of implant-based, 34.3% of pedicled-flap and 35.7% of free-flap reconstructions were recommended for PMRT. PMRT recommendation by cancer stage was 21% for T1-2 N0, 65% for T1-2 N1 and 89% for T_{any} N2 and T3 N_{any}. In multivariable analyses, patients with invasive disease undergoing implant-only reconstruction, but not pedicled-flap or free-flap reconstruction, were less likely to be recommended for PMRT than those undergoing mastectomy alone. The likelihood of being recommended for PMRT differed by region.

Conclusion: Although IBR was more likely to be performed for lower-stage cancers and in younger patients with fewer comorbidities, a third of patients undergoing IBR were recommended for PMRT. This adds to a growing body of evidence that IBR is becoming an acceptable option for women requiring PMRT. The study also highlighted regional variation in PMRT practice within the UK and Ireland, which merits further investigation.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Copyright © 2026 Tim Rattay et al. *International Journal of Breast Cancer* published by John Wiley & Sons Ltd.

1 | Introduction

Breast cancer is the most common female cancer in Europe with 557,532 new cases diagnosed in 2022 [1]. Despite advances in treatment and early diagnosis, almost 40% of women undergo mastectomy as their primary surgery [2, 3]. After surgery, radiotherapy is the second most commonly used treatment for breast cancer. Historically, long-term outcome data from randomised controlled trials have demonstrated that postmastectomy radiotherapy (PMRT) reduces recurrence rates and improves survival in all node-positive breast cancer patients [4], and population-based data have shown that use of PMRT in patients with 1–3 positive lymph nodes increased significantly between 2003 and 2012 [5, 6]. Several national treatment guidelines have recommended that radiotherapy be considered for all patients with node-positive disease after mastectomy [7–9]. However, the role of PMRT in intermediate-risk breast cancer (defined as pT1–2N1, pT3N0 or pT2N0 if also Grade 3 or with lymphovascular invasion) is less clear. Long-term results of the Selective Use of Postoperative Radiotherapy After Mastectomy (SUPREMO) Medical Research Council (MRC) Phase III clinical trial have now been published and indicate that PMRT does not impact overall survival in patients with N1 disease (1–3 positive lymph nodes) or those with N0 disease and other high-risk features [10].

Immediate breast reconstruction (IBR) is offered to women undergoing mastectomy with the aim of improving quality of life [11]. IBR remains controversial in the context of planned PMRT [12]. However, United States (US) Surveillance, Epidemiology, and End Results (SEER) data indicate that an increase in PMRT amongst women with Stage I–III breast cancer undergoing mastectomy did not lead to a concomitant decrease in IBR [6]. In fact, data from the US Mastectomy Reconstruction Outcomes Consortium (MROC) for > 2000 patients show that around 25% of implant-based and half of autologous reconstructions received PMRT [13]. Following a review of 23 observational studies, the United Kingdom (UK) National Institute for Health and Care Excellence (NICE) concluded that there was insufficient evidence to indicate worse patient outcomes from PMRT in the setting of IBR and that IBR should be offered even if adjuvant RT is anticipated [14]. At the same time, rates of IBR and, in particular, implant-only reconstruction have increased [15], yet there is a paucity of population-based data on the use of PMRT in patients undergoing IBR in the UK and other European countries [16].

In reconstructive breast surgery, the trainee research collaborative model has emerged as a time- and cost-effective method for delivering large-scale prospective studies [17, 18]. The UK Breast Reconstruction Research Collaborative of breast and plastic surgeons has delivered the iBRA-2 study to determine the impact of IBR on the delivery of adjuvant treatment [19]. The present study was undertaken to analyse patterns of PMRT amongst patients undergoing mastectomy with and without IBR enrolled in the iBRA-2 cohort.

2 | Methods

The methods of the iBRA-2 cohort study have been reported elsewhere [19, 20]. Briefly, all breast and plastic surgical units

performing mastectomy with and without IBR were invited to participate in the study via the professional associations (Association of Breast Surgery [ABS] and British Association of Plastic Reconstructive and Aesthetic Surgeons [BAPRAS]) and the breast and plastic surgery collaborative research networks (Reconstructive Surgery Trials Network [RSTN] and Mammary Fold Academic and Research Collaborative [MFAC]). Of 90 centres that expressed an initial interest, 76 centres enrolled 2526 consecutive patients between 1 July 2016 and 31 December 2016. The study sample covered approximately half of all UK breast units as well as five centres in Ireland (recruiting $n = 103$), four centres in Italy and one in Egypt (recruiting $n = 145$).

Consecutive women aged 18 or over undergoing mastectomy with or without IBR using any technique for invasive or preinvasive (ductal carcinoma in situ [DCIS]) breast cancer with curative intent were included. Patients were identified from multidisciplinary team (MDT) meetings, unit operating records and clinics. Patients were excluded if they were undergoing risk-reducing surgery (without a therapeutic mastectomy for breast cancer), partial mastectomy including wide local excision with volume replacement (latissimus dorsi [LD] miniflaps, lateral intercostal perforator [LICAP] flaps or thoracodorsal artery perforator [TDAP] flaps) or displacement techniques (therapeutic mammoplasty) and if they had distant metastatic disease.

The iBRA-2 study was classified as a service evaluation according to the NHS Health Research Authority online decision tool (<http://www.hra-decisiontools.org.uk/research/>), so ethical approval was not required. Each participating centre obtained local governance approvals prior to entering patients into the study. Data were collected prospectively, including baseline demographic and operative data. Oncological data and adjuvant treatment recommendations were collected from postoperative MDT meeting records. Pilot data collected at a number of participating sites between 1 May 2016 and 30 June 2016 suggested that adjuvant therapy was unlikely to commence earlier than 6 weeks postoperatively. Data collection in patients not requiring adjuvant treatment therefore continued from the last definitive cancer surgery until 6 weeks following surgery.

Study data were collected and managed using REDCap (Research Electronic Data Capture) electronic data capture tools hosted at the Kennedy Institute of Rheumatology, University of Oxford [21, 22]. REDCap is a secure, web-based software platform designed to support data capture for research studies, providing (1) an intuitive interface for validated data capture; (2) audit trails for tracking data manipulation and export procedures; (3) automated export procedures for seamless data downloads to common statistical packages; and (4) procedures for data integration and interoperability with external sources. For quality assurance purposes, the lead investigator at each site was asked to independently validate 5%–10% of the data. If concordance between the data entered on REDCap and that independently validated was < 90%, the unit's data were excluded from the analysis, consistent with the quality assurance procedure used in other collaborative projects.

2.1 | Study Definitions and Endpoints

Primary and secondary outcomes in iBRA-2 were selected based on current best practice [23] and national breast cancer guidelines [24]. The endpoint in the present study was the use of adjuvant radiotherapy, defined as the recorded postoperative MDT outcome 'radiotherapy recommended' or 'radiotherapy to be discussed'. For analysis purposes, patients in iBRA-2 were categorised into four groups according to the most complex surgical procedure received as follows: (i) mastectomy only (no reconstruction), (ii) mastectomy and IBR with implant-only techniques, (iii) mastectomy and IBR with pedicled flaps and (iv) mastectomy and IBR with free-flap techniques.

Implant-based procedures included any reconstruction in which only expanders/implants were used to reconstruct the breast, either with or without biological (e.g., acellular dermal matrix) or synthetic (e.g., titanium-coated polypropylene) mesh irrespective of whether the implant/expander was placed in a pre- or subpectoral position. Pedicled-flap procedures included any pedicled flap used to reconstruct the breast with or without an implant/expander, including LD and transverse rectus abdominis myocutaneous (TRAM) flaps. Free-flap procedures included any technique in which a microvascular free flap was used for IBR, including deep inferior epigastric perforator (DIEP), superficial inferior epigastric perforator (SIEA), superior and inferior gluteal artery perforator (SGAP and IGAP) and transverse upper gracilis (TUG) flaps. All complications were defined a priori [20]. Major complications were defined as any complication requiring readmission or reoperation. Minor complications were defined as those managed conservatively. An analysis of short-term complications is described elsewhere [19].

2.2 | Statistical Analysis

Data are presented per breast procedure, so any patient who fulfilled the inclusion criteria and had bilateral surgery was counted as two procedures. Descriptive summary statistics were calculated for each variable in the whole cohort and subdivided by procedure type (mastectomy only, implant-only reconstruction, pedicled-flap reconstruction and free-flap reconstruction). Categorical data were summarised by counts and percentages, and continuous data were summarised by median, interquartile range (IQR) and range. Characteristics of procedure groups were compared using chi-square tests for categorical variables and the Kruskal–Wallis test for continuous variables. Amongst patients with invasive disease, univariable and multivariable logistic regression models were used to explore associations between clinicopathological variables and use of PMRT, including patient- and procedure-related factors, namely, age, body mass index (BMI), smoking status, American Society of Anaesthesiologists' (ASA) grade, diabetes, ischaemic heart disease (IHD), other comorbidities, chemotherapy, oestrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER-2) status, lymphovascular invasion, tumour grade, multifocality and procedure type.

The correlation between proportions of patients undergoing PMRT and IBR by region was determined using Pearson's *r* statistic. Whether different regions of the UK and Ireland had

differing rates of recommending PMRT was assessed using multivariable logistic regression, adjusted for BMI, comorbidities, smoking status, ASA, ER and HER-2 status, lymphovascular invasion, multifocality and tumour grade, with clustering by centre. This was performed separately for patients undergoing mastectomy only and those undergoing any IBR. All analyses were performed in STATA 19.5 (StataCorp, Texas).

3 | Results

Of 2526 patients recruited into the iBRA-2 study, 1528 underwent mastectomy only, 666 underwent implant-only reconstruction, 105 received pedicled flaps and 227 underwent free-flap reconstruction. As 80 patients had bilateral cancer surgery and there were 16 procedures with missing outcome data, a total of 2590 breast procedures were included in the analysis. On a per-breast basis, Table 1 and Supporting Information 1: Table S1 summarise patient demographics and adjuvant therapy decisions by procedure type. Patients undergoing mastectomy alone ($n = 1559$ breast procedures) were older than those undergoing IBR and were more likely to have comorbidities as indicated by ASA grade. Patients undergoing IBR were more likely to have lower-stage cancers. Adjuvant chemotherapy was more likely to be recommended after mastectomy only than after IBR. Adjuvant radiotherapy was recommended or for discussion in 46.0% of mastectomies, in 32.5% of implant-based reconstructions and in 34.3% and 35.7% of pedicled-flap and free-flap reconstructions, respectively.

3.1 | PMRT Recommendation by Tumour and Nodal Stage

Figure 1 shows the proportion of patients on a per-breast basis ($n = 2590$) recommended for PMRT by tumour stage. Out of all patients with T3, N2 or N3 stage disease, 89% were recommended for radiotherapy, whilst 64.7% of patients with N1 stage disease were recommended for radiotherapy. Interestingly, 13.2% of Tis and 21.1% of N0 stage patients were also recommended for radiotherapy. When subdivided by tumour and nodal stage, there was little difference in PMRT recommendation percentages between surgical procedure types (Supporting Information 1: Table S2).

Table 2 and Supporting Information 1: Table S2 show the patient and tumour variables associated with PMRT recommendation for patients with invasive disease. In multivariable analysis, patients with larger tumours and more advanced lymph node stage were more likely to receive a recommendation for PMRT. Patients undergoing pedicled-flap or free-flap reconstruction were as likely as those having mastectomy to be recommended for PMRT. However, women receiving implant-only reconstruction were less likely to be offered PMRT compared to patients undergoing mastectomy only (adjusted odds ratio 0.65, 95% confidence interval: 0.43–0.97, $p = 0.035$).

3.2 | Regional Variation in PMRT

Excluding 145 patients from five centres outside the UK and Ireland, Supporting Information 2: Figure S1 shows no

TABLE 1 | Patient demographics and proportion of patients offered adjuvant radiotherapy by type of surgical procedure.

Per-breast data	Mastectomy only (n = 1559, 60.2%)		Implant reconstruction (n = 696, 26.9%)		Pedicled-flap reconstruction (n = 105, 4.0%)		Free-flap reconstruction (n = 230, 8.9%)		Total (n = 2590, 100%)		p value
		54–75	50	43–57	52	47–60	50	45–56	58	48–69	
Age (median, IQR)	65	54–75	50	43–57	52	47–60	50	45–56	58	48–69	<0.001
ASA grade (n, %)											
1	339	21.7%	288	41.4%	40	38.1%	60	26.1%	727	28.1%	<0.001
2	918	58.9%	385	55.3%	61	58.1%	161	70.0%	1525	58.9%	
3	288	18.5%	23	3.3%	3	2.9%	8	3.5%	322	12.4%	
4	6	0.4%	0	0.0%	0	0.0%	0	0.0%	6	0.2%	
Missing data	8	0.5%	0	0.0%	1	1.0%	1	0.4%	10	0.4%	
T stage (n, %)											
Tis	141	9.0%	162	23.3%	26	24.8%	57	24.8%	386	14.9%	<0.001
T1-2	1206	77.3%	472	67.8%	67	63.8%	142	61.7%	1887	72.9%	
T3	190	12.2%	54	7.8%	9	8.6%	18	7.8%	271	10.5%	
Missing data	22	1.4%	8	1.2%	3	2.9%	13	5.7%	46	1.8%	
N stage (n, %)											
N0	904	58.4%	517	75.3%	71	67.6%	163	70.9%	1655	63.9%	<0.001
N1	391	23.9%	126	15.8%	16	15.2%	45	19.6%	578	22.3%	
N2	250	15.8%	42	5.9%	12	11.4%	14	6.1%	318	12.3%	
Missing data	14	1.9%	11	3.0%	6	5.7%	8	3.5%	39	1.5%	
Chemotherapy (n, %)											
Recommended	395	25.3%	154	22.1%	25	23.8%	39	17.0%	613	23.7%	0.001
For discussion	135	8.7%	37	5.3%	5	4.8%	9	3.9%	186	7.2%	
For Oncotype DX	93	6.0%	65	9.3	5	4.8%	17	7.4%	180	7.0%	
Received	236	15.1%	132	19.0%	21	20.0%	44	19.1%	433	16.7%	
Missing data	2	0.1%	0	0%	0	0%	0	0%	2	0.1%	
Radiotherapy (n, %)											
Recommended	631	40.5%	207	29.7%	35	33.3%	63	27.4%	936	36.1%	<0.001
For discussion	86	5.5%	19	2.7%	1	1.0%	19	8.3%	125	4.8%	




FIGURE 1 | Proportion of patients (%; per-breast data) recommended for postmastectomy radiotherapy by tumour stage.

TABLE 2 | Unadjusted and adjusted* odds ratios of PMRT recommendation in patients with invasive disease ($n = 2204$ breast procedures).

Per-breast data	Univariable analysis			Multivariable analysis		
	Odds ratio	95% CI	<i>p</i> value	Adjusted odds ratio	95% CI	<i>p</i> value
Tumour size (invasive)						
0–9 mm	1	Comparator		1	Comparator	
10–20 mm	0.74	0.57–0.95	0.020	0.65	0.46–0.91	0.012
20–50 mm	1.91	1.48–2.46	<0.001	1.18	0.84–1.67	0.340
> 50 mm	14.08	8.91–22.24	<0.001	11.76	6.18–22.40	<0.001
Lymph nodes						
N0	1	Comparator		1	Comparator	
N1	6.88	5.19–9.13	<0.001	4.77	3.45–6.60	<0.001
N2	27.19	17.43–42.40	<0.001	16.34	9.31–28.69	<0.001
Type of surgery						
Mastectomy only	1	Comparator		1	Comparator	
Implant	0.61	0.46–0.81	0.001	0.65	0.43–0.97	0.035
Pedicled flap	0.77	0.44–1.37	0.383	0.63	0.32–1.25	0.184
Free flap	0.80	0.53–1.21	0.297	0.74	0.38–1.45	0.379

Abbreviation: CI, confidence interval.

*The multivariable analysis also included age, body mass index, comorbidities (ischaemic heart disease, diabetes and other), smoking status, chemotherapy recommendation, ASA grade, ER and HER-2 status, lymphovascular invasion, multifocality and tumour grade. Full results are shown in Supporting Information 1: Table S2.

correlation between the proportion of patients recommended for PMRT and the proportion receiving IBR across the 14 regions ($r = -0.23$, $p = 0.41$).

Table 3 shows the proportion of patients recommended for PMRT subdivided by region, excluding centres outside the UK and Ireland. In adjusted analyses, women undergoing mastectomy in Northern Ireland/Ireland, the North of

England, Yorkshire/Humberside, the West Midlands and Scotland were less likely to be recommended for PMRT than those in London and the Southeast. For patients undergoing IBR, the regional numbers were too small to subdivide further by procedure type. Nevertheless, women undergoing IBR in Yorkshire/Humberside were less likely to be recommended for PMRT than those in London and the Southeast of England.

TABLE 3 | Adjusted* odds ratios of PMRT recommendation by region in patients undergoing mastectomy only and those undergoing IBR.

Per-breast data	Mastectomy only (<i>n</i> = 1513)			Breast reconstruction (any) (<i>n</i> = 932)		
	Percentage RT recommended	aOR (95% CI)	<i>p</i> value	Percentage RT recommended	aOR (95% CI)	<i>p</i> value
London/Southeast	53%	1		39%	1	
East	48%	0.84 (0.46–1.52)	0.562	39%	0.71 (0.25–1.99)	0.512
East Midlands	49%	0.93 (0.46–1.89)	0.837	24%	0.45 (0.17–1.20)	0.110
Yorkshire/Humber	37%	0.49 (0.26–0.91)	0.024	24%	0.31 (0.11–0.83)	0.020
NI/Ireland	52%	0.30 (0.15–0.60)	0.001	47%	1.85 (0.65–5.28)	0.251
North	41%	0.43 (0.22–0.84)	0.014	25%	0.43 (0.17–1.05)	0.065
Scotland	44%	0.33 (0.17–0.64)	0.001	48%	1.32 (0.46–3.80)	0.613
Wales/Southwest	47%	0.74 (0.37–1.47)	0.387	34%	1.81 (0.61–5.35)	0.282
West Midlands	47%	0.51 (0.28–0.95)	0.034	37%	1.02 (0.23–4.50)	0.974

Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; NI, Northern Ireland.

*Multivariable analysis also included age, body mass index, comorbidities (ischaemic heart disease, diabetes and other), smoking status, chemotherapy recommendation, ASA grade, ER and HER-2 status, lymphovascular invasion, multifocality, lymph node status and tumour size and grade. Full results are shown in Supporting Information 1: Table S3.

4 | Discussion

The aim of this study was to analyse patterns of PMRT amongst patients undergoing mastectomy with and without IBR. The primary outcome and rates of postoperative complications in the iBRA-2 patient cohort have been reported elsewhere [19]. In relation to PMRT, the present study found that between 32.5% and 35.7% of women undergoing IBR were recommended for or were for discussion of radiotherapy compared to 46% of those receiving mastectomy. These figures are in keeping with several previously published observational studies showing that between 29% and 43% of patients with IBR are irradiated [13, 18, 25, 26]. IBR was more likely to be performed for lower-stage cancers and in younger patients with fewer comorbidities. Nevertheless, in patients with invasive disease, after adjusting for patient and tumour variables, only women undergoing implant-only reconstruction were statistically less likely to be recommended for PMRT. This was not the case for those undergoing pedicled-flap or free-flap reconstruction. This adds to a growing body of evidence that IBR is becoming an acceptable option for women requiring PMRT [27–29] and that PMRT is only one of many factors in the decision for/against IBR, which include consideration of patient and oncological factors as well as surgeon and patient preferences. Indeed, it has been shown that breast cancer MDTs cannot predict with certainty whether a patient will require adjuvant PMRT [30].

There was no correlation between the proportion of patients recommended for PMRT and the proportion of IBR across different UK regions. This suggests that participating centres offered all types of IBR irrespective of whether PMRT was expected in the adjuvant setting, in keeping with findings from a similar US population-based study [6] and current clinical guidelines [14]. The individual choice of IBR technique is likely to depend on several patient and surgical factors as well as locally available expertise and access to immediate free-flap reconstruction. However, in patients requiring PMRT, implant-only IBR may be associated

with more complications compared to autologous IBR [13, 18]. Follow-up data from two prospective cohort studies showed lower satisfaction amongst patients with irradiated implant-only reconstruction [31, 32]. Nevertheless, further work is required to establish the impact of PMRT on the long-term outcomes of IBR to provide high-quality data to inform practice. Initial results from nonrandomised studies comparing neoadjuvant versus adjuvant radiotherapy in patients scheduled for IBR are promising and demonstrate the feasibility and safety of this approach [33], but the results of randomised trials will take some years to mature.

Compared to previous population-based analyses showing between 30.3% and 40.5% of patients with N1 disease (1–3 positive lymph nodes) receiving PMRT before 2012 [5, 6], in our study, 64.7% of such patients as well as 87.8% of patients with T3N0 disease, representing 21.7% (total *n* = 562) of the study population, were recommended for PMRT. This confirmed the trend of a hitherto increasing number of patients with N1 and T3 disease being considered for PMRT [7, 8, 34]. Following publication of the SUPREMO trial [10], it remains to be seen if PMRT use for intermediate-risk breast cancer (defined as pT1–2N1, pT3N0 or pT2N0 if also Grade 3 or with lymphovascular invasion) will reduce, as treatment recommendations for this group have recently been updated in national guidelines in the light of other recently published trials [9, 35]. Interestingly, the proportion of patients in our study with noninvasive cancer receiving PMRT (13.2%) appears relatively high compared to an earlier UK study [36], although our study was not restricted to the breast screening population, and the receipt of radiotherapy following mastectomy for DCIS may be related to margin status, grade and presence of microinvasion.

Subdividing the data from the UK regions and Ireland, we found that patients in Northern Ireland/Ireland, Scotland, the North of England and Yorkshire/Humberside were significantly less likely to be recommended for PMRT. This highlights some interesting geographical variation, which merits further

investigation. A US-based study found that the density of radiation oncology practices was associated with receipt of PMRT in patients with N1 stage breast cancer [5].

There is accumulating evidence that individual patient and tumour molecular profiles will be able to predict the response to adjuvant treatment. Several Phase III trials have reported on the effectiveness of the 70- or 21-gene recurrence scores in selecting patients for adjuvant chemotherapy [37–39]. Genomic-adjusted radiation dose (GARD) therapy may allow personalisation of radiotherapy on the basis of the biological effect of a given physical dose of radiation, calculated using individual tumour genomics, and has been shown to predict time to recurrence and overall survival [40]. In terms of complications from IBR, predictive risk models have been validated in the US with receipt of PMRT (or not) as a predictor [41, 42]. Other risk prediction models for individual radiotherapy side effects in the breast have been validated [43, 44], though none in the setting of IBR. In the future, personalised medicine approaches including the patient germline and tumour genomic profile may aid decision-making around IBR and PMRT.

4.1 | Strengths and Limitations

To our knowledge, this is the largest cohort study to date in the UK and Ireland investigating patterns of PMRT in patients undergoing mastectomy with and without IBR, but there are several limitations. Due to its observational design, the study is at risk of bias. Patients were recruited consecutively from participating centres, but there were baseline differences between the treatment groups. Although we adjusted for known confounders such as cancer stage, patient age, BMI, smoking status and ASA grade and excluded noninvasive disease from some of our analyses, we acknowledge that it is not possible to adjust for all potential confounders. Our study included patients from 71 centres in the UK and Ireland as well as five centres in Italy and Egypt. It is possible that participating units differed from those not taking part. However, approximately half of all UK breast units were represented in the study.

Due to the short follow-up period (up to initiation of first adjuvant treatment), we were only able to analyse treatment recommendations and were unable to ascertain successful receipt or completion of PMRT in all patients. It was not possible to follow patients up to completion of adjuvant therapy with this surgical trainee collaborative design, but collaborations with oncology trainees should allow us to address this issue in the future. Moreover, a data linkage study is planned to explore long-term oncological outcomes in terms of local recurrence, disease-free survival and overall survival. Whilst it is not possible to establish causation with this observational study design, the design and conduct of randomised controlled trials in the setting of IBR are perceived as difficult due to patient and surgeon preferences for type and timing of breast reconstruction [26].

4.2 | Conclusions

Although IBR was more likely to be performed for lower-stage cancers and in younger patients with fewer comorbidities,

approximately one-third of patients in this population-based cohort undergoing IBR were recommended for PMRT. About two-thirds of all patients with T1-2 N1 disease were recommended for PMRT, which reflects clinical treatment guidelines for this patient group at the time of study recruitment, and the present study provides an estimate of patients potentially eligible for treatment de-escalation. Within the UK and Ireland, the study has also highlighted regional variation in PMRT practice that merits further investigation. Further work is ongoing to establish the impact of PMRT on the long-term outcomes of different types of IBR to help women and surgeons make more informed decisions about breast reconstruction options.

Author Contributions

S.P. and T.R. conceived the study design (subgroup analysis). T.R. contributed to the design, conduct of the study, analysis of the data and interpretation of the results and wrote the first draft of the paper. A.T. performed the analysis, contributed to data interpretation and drafted the manuscript. R.L.O.C., T.R., R.V.D., N.L.P. B., C.H. and S.P. contributed to the study design for iBRA-2. M.D.G. and J.S. contributed to the study design and interpretation of the data.

Acknowledgments

Members of the iBRA-2 steering group are (in alphabetical order) Nicola L. P. Barnes, Jane Blazeby, Elizabeth Conroy, Rajiv V. Dave, Matthew D. Gardiner, Adrian Harnett, Chris Holcombe, Ciara O'Brien, Rachel L. O'Connell, Shelley Potter, Tim Rattay and Joanna Skillman. Investigators of the iBRA-2 Study Group (contact Prof. Shelley Potter, shelley.potter@bristol.ac.uk) and the Breast Reconstruction Research Collaborative (contact Prof. Matthew D. Gardiner, matthew.gardiner@kennedy.ox.ac.uk) are PubMed-citable collaborators and are listed in alphabetical order by centre: Aberdeen Royal Infirmary, NHS Grampian; Alain Curnier, Amir Tadros, Ivan Depasquale, Yazan A. Masannat, Elizabeth Smyth, Mairi Fuller, Roger Bourne, Steven Heys, Ishrak Hamo. Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust; Fatima Aloraifi, Laura Fopp, Radhika Bali, Sarah Bache, Sarah L. Benyon, Michael S. Irwin, Amit Agrawal, Charles M. Malata. Airedale NHS Foundation Trust; Claire Murphy. Basildon and Thurrock Hospitals NHS Foundation Trust; Adam Misky, Dennis Wayne Chicken. Beaumont Hospital and the RCSI; Nassreen Abdullah, Arnold D. K. Hill. Belfast City Hospital, Belfast Health and Social Care Trust; Carolyn Cullinane, Gareth Irwin, Stuart A. McIntosh, Sigi Refsum, Samantha Sloan, Peter Mallon. Betsi Cadwaladr University Health Board; Chiara Sirianni, Ilyas Khattak. Blackpool Teaching Hospitals NHS Foundation Trust; Geerthan Nagachandra, Pasupathy Kiruparan, Debasish Debanth. Breast Care Centre, North Bristol NHS Trust, Southmead Hospital, Bristol; Simon Davey, Terry-Ann Curran, Matilda Svenning, Sasirekha Govindarajulu, Zenon Rayter, Rachel Ainsworth, Simon Cawthorn, Ajay Sahu, Sherif Wilson, Elena Prousskaia. Breast Unit Department, University of Naples 'Federico II', Naples, Italy; Antonello Accurso, Nicola Rocco, Rosa Di Micco, Gennaro Limite. Breast Unit Department S. Maria delle Grazie ASL Na 2 Pozzuoli; Raffaele Ceccarino, Raffaele Liccardo, Guido Coco. Broomfield Hospital, Mid Essex Hospital Services NHS Trust; Metin Nizamoglu, Mary Morgan, Venkat Ramakrishnan. Cannizzaro Hospital, Catania; Giuseppe Catanuto. Castle Hill Hospital, Hull and East Yorkshire Hospitals NHS Trust; Alex Wilkins, Penelope McManus, Peter Kneeshaw, Kartikae Grover, Tapan Mahapatra, Brendan Wooler, Bilal Elahi, Naila Ihsan. Charing Cross Hospital, Imperial College Healthcare NHS Trust; Alexandra Bucknor, Dimitris Reissis, Judith Hunter, Simon Wood, Navid Jallali, Francis P. Henry, Liaquat S. Verjee, Jason Lee. Chesterfield Royal Hospital NHS

Foundation Trust; Shazia M. Khan, Iman Azmy, Julia Massey, Ciaran Hollywood, Michael Oluwajana. Countess of Chester Hospital NHS Foundation Trust; Sonia Bathla, Joanna Seward, Claudia Harding-MacKean. Darent Valley Hospital, Dartford and Gravesham NHS Trust; Risha Lane, Kothandaraman Murali, Bashishta Biswas, Pawel Trapszo, Seema Seetharam. Dorset County Hospital NHS Foundation Trust; Katy Kennedy, Louise Alder, Tomasz Graja. East Cheshire NHS Trust; Khalid Amin, Jalal Kokan, Chandeena Roshanlall. Edinburgh Breast Unit, Western General Hospital, NHS Lothian; Emma Gill, Dhananjay Kulkarni, J. M. Dixon, Oliver Young, Talha Saleem. Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde; M. Biddle, Marie Kearns, Eva Weiler-Mithoff, Ben Chew, Andy Malyon, John Scott, David McGill, Iain Mackay. Glenfield Hospital, University Hospitals of Leicester; Salena Bains, Sara Barrows, Tim Rattay, Simon Pilgrim, Sheila Shokuhi, Kelly Lambert, Frances Kenny, Kalliope Valassiadou, Monika Kaushik, Jaroslaw Krupa, Dimitris Dragoumis. Good Hope Hospital, Heart of England NHS Foundation Trust; Quratul Ain, Pavlos Lampropoulos, Sarah Moss, Haitham Khalil, Anwar Haq, Balapathiran Balasubramanian. Guy's and St. Thomas' NHS Foundation Trust; Petros Charalampoudis, Hisham Hamed, Ashutosh Kothari, Tibor Kovacs, Michael Douek. Harrogate and District NHS Foundation Trust; Iftikhar Mehmood, Biswajit Ray, Matthew Adelekan. Homerton University Hospital NHS Foundation Trust; Laura Humphreys, Salim Tayeh, Christina Choy, Laila Parvanta. Istituto Oncologico Veneto, Padova, Italy; Silvia Michieletto, Tania Saibene. James Paget University Hospitals NHS Foundation Trust; James O'Brien, Sue Down, Sarah Downey, Jerome Pereira. Lincoln County Hospital, United Lincolnshire Hospitals NHS Trust; A. S. Sami, Anzors Gvaramadze, Jibril A. Jibril, Dinesh Thekkinkattil. Llanelli Peony Breast Unit; S. Udayasankar, Saira Khawaja, Yousef Shariha, Simon Holt. Luton and Dunstable University Hospital; Ruth James, Hirah Rizki, Katharine Kirkpatrick, Duraisamy Ravichandran, Deepak Shrestha. Maidstone and Tunbridge Wells NHS Trust; Ellora Barua, Deepika Akolekar. Mid Cheshire Hospitals NHS Foundation Trust; Ahmed Hamad, Eleftheria Kleidi, Susan Hignett, Vanessa Pope, Salma Naseem. Milton Keynes University Hospital NHS Foundation Trust; Jennifer Isherwood, Rachel Soulsby, Amanda Taylor, Kian Chin. Morrision Hospital, Abertawe Bro Morgannwg University Health Board; Dai Nguyen. Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust; Francesca Guest, Amanda Thorne. Nevill Hall Hospital, Aneurin Bevan University Health Board; Valentina Lefemine. Norfolk and Norwich University Hospitals NHS Foundation Trust; Chris Kirchhoff, Declan C. Murphy, Michelle Lo, Ruth Harcourt, Simon J. Pain, Maged I. Hussien, Katalin Zechmeister, E. M. Sassoon, Andrea Figus, Richard M. Haywood, Rozina Ali, Susanna Alexander, Adrian Harnett, Konstantinos Geropantaz, Daniel Epurescu. North Middlesex University Hospital; Rebecca Lewis, Oladapo Fafemi, Jasdeep Gahir, Tasha Gandamihardja. Nottingham Breast Institute, Nottingham University Hospitals NHS Trust; Jennett Kelsall, Nazli Muhibullah, Charlene Otieno, Fayyaz Mazari, Marta Dauria, Lisa Whisker, Douglas Macmillan, Eleanor Gutteridge, Tuabin Rasheed, Hazem Khout, Kristjan Asgeirsson, Stephen McCulley. Ospedale Santa Chiara, University of Pisa, Italy; Maria Donatella Mariniello, Manuela Roncella, Matteo Ghilli, Livio Colizzi, Elena Rossetti, Marzia Lo Russo, Loredana Fustaino, Alessandro Quattrini Li. Oxford University Hospitals NHS Foundation Trust; Kate L. Harvey, Rebecca Windle, Dionysios Dennis Remoundos, Pankaj Roy, Gael MacLean, Asha Adwani. Peterborough City Hospital, North West Anglia NHS Foundation Trust; Elena Popa, Steven Goh, Geeta Shetty. Poole Hospital NHS Foundation Trust; Sarah Clark. Portsmouth Hospitals NHS Trust; Lorenzo Bernaudo, Avi Agrawal, Lucy Mansfield. Princess Alexandra Hospital NHS Trust; Sally Tebbal, Ashraf Patel, Veronica Grassi. Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust; Ojas Pujji, Kathryn Hamnett, Naren Basu. Royal Bolton Hospital, Bolton NHS Foundation Trust; Emily Granger, Michael Durbar, Panagiotis Pikoulas, Clare Garnsey, Philip Walker, Angela J. Volleremere, Ioannis Michalakakis. Royal Devon and Exeter NHS Foundation Trust; Robin

Jones, Mina Youssef, Charlotte Ives, Mohammad Masood, Julie Dunn, Sisse Olsen, Douglas Ferguson, Rachel Tillet. Royal Free London NHS Foundation Trust; Anna Allan, Alex Woollard, Rebecca Canny, Alexander Woollard, Afshin Mosahebi, Stephen Hamilton, Shadi Ghali, Daniel Marsh, Jagdeep Chana, Nilesh Sojitra, Ibbi Younis. Royal Hampshire County Hospital, Hampshire Hospitals NHS Foundation Trust; Dick Rainsbury, Natalie Chand, Vasileios Kalles, Anne Stebbing, Kevin Harris, Siobhan Laws. Royal Liverpool and Broadgreen University Hospitals NHS Trust; Chris Holcombe, Anne Tansley, Geraldine Mitchell, Emma de Sousa, Julia Henderson, Mysore Chandrashekar. Royal Marsden NHS Foundation Trust; Bernadette Pereira, Chloe Constantinou, Dalia Elfadl, Foivos Irakleidis, Izaro Hernan, Miriam Byrne, Natalie To, Rachel O'Connell, Jennifer Rusby, Peter Barry, Katherine Krupa, William Allum, Fiona MacNeill, Nicola Roche, Gerald Gui, Kelvin Ramsey, Paul Harris, Stuart James, Kieran Power. Royal United Hospitals Bath NHS Foundation Trust; Shelley Potter, Richard Sutton, Jamie McIntosh, Nicola Laurence. Royal Victoria Infirmary, Newcastle Upon Tyne Hospitals NHS Foundation Trust; Louise MacLennan, Robert Milligan, Henry Cain, Adam Critchley, Joe O'Donoghue, Loraine Kalra, Nick Collis. Salisbury NHS Foundation Trust; Gina Weston-Petrides, Roanne Fiddes, Victoria Brown, Anna Aertssen, Diana Slade-Sharman, Mansoor Khan, Caroline McGuiness. Sant'Andrea Hospital of Rome; Vittoria Amorosi, Fabio Santanelli di Pompeo. St. Bartholomew's Hospital, Barts Health NHS Trust; Georgios Exarchos, Natasha Jiwa, Jennifer Hu, Serena Ledwidge, Laura Johnson, Anthony Peel, Naseem Dhooma. St. Vincent's University Hospital, Dublin; Eric Farrell, Liam Devane, Ruth Tevlin, Enda McDermott, Ruth Prichard, Denis Evoy, Jane Rothwell, James Geraghty, Colin Morrison, Catriona Lawlor. St. James University Hospital, The Leeds Teaching Hospitals NHS Trust; Fiona Langlands, Lauren Taylor, Philip Turton, Raj Achuthan, Kieran Horgan, Shireen McKenzie, Brian Hogan, Mark Lansdown, Channegowda Navin. The Ipswich Hospital NHS Trust; Liz Sherwin, Caroline Mortimer, Neeraj Garg. The Mid Yorkshire Hospitals NHS Trust; Rahma Adam, Tahera Arif, Zbigniew Kryjak, Deedar Ali, Ravi Sowdi. The Royal Wolverhampton NHS Trust; Elena Fage, Senthurun Mylvaganam, Pilar Matey, Raghavan Vidya, Tapan Sircar. University Hospital of North Tees; Oubida Asaad, Pud Bhaskar, Matei Dordea. University Hospital of South Manchester; Ada Chrysafi, Damian McCartan, Rajiv Dave, Rachel Foster, Rebecca Wilson, Sylvia Okwemba, Yousef Majeed, Ciara O'Brien, Vinod Mathen, John Murphy, Nicola Barnes, Ashu Gandhi, James Harvey, Cliona C. Kirwan, Richard Johnson. University Hospitals Coventry & Warwickshire; Krupali Patel, Maria Dalmau Ribas, Natali Vigneswaran, Tom Challoner, Joanna Skillman, Alan Park, Maged Rizkalla, Abigail Tomlins, Kat McEvoy. University Hospitals of North Midlands NHS Trust; Sadaf Jafferbhoy, Soni Soumian, Sankaran Narayanan, Robert Kirby. West Hertfordshire Hospitals NHS Trust; Sladana Bajrusevic, Joseph Maalo, Michalis Charalambous, Lee Min Lai, Kelvin Chong, Simon Thomson, Sherif Monib. Whiston Hospital, St. Helens and Knowsley Teaching Hospitals NHS Trust; Leena Chagla, Riccardo Audisio, Rieka Taghizadeh, Azhar Iqbal. Wirral University Teaching Hospital NHS Foundation Trust; Karen James, Maria Callaghan, Shabbir Poonawala, Jonathan Lund, Raman Vinayagam. Worcestershire Acute Hospitals NHS Trust; Sadaf Jafferbhoy, Steven Thrush, Rachel Bright Thomas, Michelle Mullan, Jevan Taylor. York Teaching Hospital NHS Foundation Trust; Ryo Yoshimura, Tom Mathew, Ben Mancey Jones, Kailas Munot, Rana Nasr, Jenny Piper, Deena El-Sharief. Zagazig University Hospital, Egypt; Mohammed Mustafa.

Funding

Funding was provided by the NIHR Leicester Biomedical Research Centre ([10.13039/501100020013](https://doi.org/10.13039/501100020013)), the NIHR Bristol Biomedical Research Centre ([10.13039/100015250](https://doi.org/10.13039/100015250)) and the National Institute for Health Research ([10.13039/501100000272](https://doi.org/10.13039/501100000272); CL-2017-11-02, DRF-2014-07-079 and CS-2016-16-019).

Disclosure

A previous version of this paper was posted as a preprint on Research Square at <https://www.researchsquare.com/article/rs-1108079/v1>. All authors read and approved the final manuscript. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Conflicts of Interest

T.R. is supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre and was previously an NIHR Clinical Lecturer (CL-2017-11-02) and NIHR Doctoral Research Fellow (DRF-2014-07-079). S.P. is supported by the NIHR Bristol Biomedical Research Centre and was previously an NIHR Clinician Scientist (CS-2016-16-019). The other authors have no competing interests to declare.

Data Availability Statement

The datasets generated during and/or analysed in the current study are available from the corresponding author on reasonable request.

References

1. J. E. M. Ferlay, F. Lam, M. Laversanne, et al., *Bray F Global Cancer Observatory: Cancer Today* (International Agency for Research on Cancer, 2024).
2. C. A. Garcia-Etienne, M. Tomatis, J. Heil, et al., "Mastectomy Trends for Early-Stage Breast Cancer: A Report From the EUSOMA Multi-Institutional European Database," *European Journal of Cancer* 48, no. 13 (2012): 1947–1956, <https://doi.org/10.1016/j.ejca.2012.03.008>.
3. K. L. Kummerow, L. Du, D. F. Penson, Y. Shyr, and M. A. Hooks, "Nationwide Trends in Mastectomy for Early-Stage Breast Cancer," *JAMA Surgery* 150, no. 1 (2015): 9–16, <https://doi.org/10.1001/jamasurg.2014.2895>.
4. P. McGale, C. Taylor, C. Correa, et al., "Effect of Radiotherapy After Mastectomy and Axillary Surgery on 10-Year Recurrence and 20-Year Breast Cancer Mortality: Meta-Analysis of Individual Patient Data for 8135 Women in 22 Randomised Trials," *Lancet* 383, no. 9935 (2014): 2127–2135, [https://doi.org/10.1016/S0140-6736\(14\)60488-8](https://doi.org/10.1016/S0140-6736(14)60488-8).
5. N. Ohri, M. P. Sittig, C. J. Tsai, et al., "Trends and Variations in Postmastectomy Radiation Therapy for Breast Cancer in Patients With 1 to 3 Positive Lymph Nodes: A National Cancer Data Base analysis," *Cancer* 124, no. 3 (2018): 482–490, <https://doi.org/10.1002/cncr.31080>.
6. L. L. Frasier, S. Holden, T. Holden, et al., "Temporal Trends in Postmastectomy Radiation Therapy and Breast Reconstruction Associated With Changes in National Comprehensive Cancer Network Guidelines," *JAMA Oncology* 2, no. 1 (2016): 95–101, <https://doi.org/10.1001/jamaoncol.2015.3717>.
7. National Institute for Health and Care Excellence, *Early and Locally Advanced Breast Cancer: Diagnosis and Management* (National Institute for Health and Clinical Excellence, 2018).
8. F. Wenz, E. Spiek, W. Budach, et al., "DEGRO Practical Guidelines for Radiotherapy of Breast Cancer IV: Radiotherapy Following Mastectomy for Invasive Breast Cancer," *Strahlentherapie und Onkologie* 190, no. 8 (2014): 705–714, <https://doi.org/10.1007/s00066-014-0687-0>.
9. R. B. Jimenez, Y. Abdou, P. Anderson, et al., "Postmastectomy Radiation Therapy: An ASTRO/ASCO/SSO Clinical Practice Guideline," *Journal of Clinical Oncology* 43, no. 30 (2025): 3292–3311, <https://doi.org/10.1245/s10434-025-18057-3>.
10. I. H. Kunkler, N. S. Russell, N. Anderson, et al., "Ten-Year Survival After Postmastectomy Chest-Wall Irradiation in Breast Cancer," *New England Journal of Medicine* 393, no. 18 (2025): 1771–1783, <https://doi.org/10.1056/NEJMoa2412225>.
11. D. Harcourt, and N. Rumsey, "Psychological Aspects of Breast Reconstruction: A Review of the Literature," *Journal of Advanced Nursing* 35, no. 4 (2001): 477–487, <https://doi.org/10.1046/j.1365-2648.2001.01865.x>.
12. P. J. Duxbury, A. Gandhi, C. C. Kirwan, Y. Jain, and J. R. Harvey, "Current Attitudes to Breast Reconstruction Surgery for Women at Risk of Post-Mastectomy Radiotherapy: A Survey of UK Breast Surgeons," *Breast* 24, no. 4 (2015): 502–512, <https://doi.org/10.1016/j.breast.2015.05.002>.
13. R. Jagsi, A. O. Momoh, J. Qi, et al., "Impact of Radiotherapy on Complications and Patient-Reported Outcomes After Breast Reconstruction," *JNCI: Journal of the National Cancer Institute* 110, no. 2 (2018): 157–165, <https://doi.org/10.1093/jnci/djx148>.
14. National Institute for Health and Care Excellence, *Evidence Reviews for Postmastectomy Radiotherapy. Early and Locally Advanced Breast Cancer: Diagnosis and Management* (National Institute for Health and Care Excellence, 2018).
15. J. C. Mennie, P. N. Mohanna, J. M. O'Donoghue, R. Rainsbury, and D. A. Cromwell, "National Trends in Immediate and Delayed Post-Mastectomy Reconstruction Procedures in England: A Seven-Year Population-Based Cohort Study," *European Journal of Surgical Oncology (EJSO)* 43, no. 1 (2017): 52–61, <https://doi.org/10.1016/j.ejso.2016.09.019>.
16. J. de Boniface, H. Coudé Adam, A. Frisell, et al., "Long-Term Outcomes of Implant-Based Immediate Breast Reconstruction With and Without Radiotherapy: A Population-Based Study," *British Journal of Surgery* 109, no. 11 (2022): 1107–1115, <https://doi.org/10.1093/bjs/znac283>.
17. R. L. O'Connell, E. Baker, A. Trickey, et al., "Current Practice and Short-Term Outcomes of Therapeutic Mammoplasty in the International Team Multicentre Prospective Cohort Study," *Journal of British Surgery* 105, no. 13 (2018): 1778–1792, <https://doi.org/10.1002/bjs.10959>.
18. S. Potter, E. J. Conroy, R. I. Cutress, et al., "Short-Term Safety Outcomes of Mastectomy and Immediate Implant-Based Breast Reconstruction With and Without Mesh (iBRA): A multicentre, prospective cohort study," *Lancet Oncology* 20, no. 2 (2019): 254–266, [https://doi.org/10.1016/S1470-2045\(18\)30781-2](https://doi.org/10.1016/S1470-2045(18)30781-2).
19. R. L. O'Connell, T. Rattay, R. V. Dave, et al., "The Impact of Immediate Breast Reconstruction on the Time to Delivery of Adjuvant Therapy: The iBRA-2 Study," *British Journal of Cancer* 120, no. 9 (2019): 883–895, <https://doi.org/10.1038/s41416-019-0438-1>.
20. R. Dave, R. O'Connell, T. Rattay, et al., "The iBRA-2 (Immediate Breast Reconstruction and Adjuvant Therapy Audit) Study: Protocol for a Prospective National Multicentre Cohort Study to Evaluate the Impact of Immediate Breast Reconstruction on the Delivery of Adjuvant Therapy," *BMJ Open* 6, no. 10 (2016): e012678, <https://doi.org/10.1136/bmjopen-2016-012678>.
21. P. A. Harris, R. Taylor, B. L. Minor, et al., "The REDCap Consortium: Building an International Community of Software Platform Partners," *Journal of Biomedical Informatics* 95 (2019): 103208, <https://doi.org/10.1016/j.jbi.2019.103208>.
22. P. A. Harris, R. Taylor, R. Thielke, J. Payne, N. Gonzalez, and J. G. Conde, "Research Electronic Data Capture (REDCap)—A Metadata-Driven Methodology and Workflow Process for Providing Translational Research Informatics Support," *Journal of Biomedical Informatics* 42, no. 2 (2009): 377–381, <https://doi.org/10.1016/j.jbi.2008.08.010>.
23. Association of Breast Surgery, *Oncoplastic Breast Reconstruction - Guidelines for Best Practice* (British Association of Plastic Reconstruction and Aesthetic Surgeons, 2012).

24. National Institute for Health and Care Excellence, *Early and Locally Advanced Breast Cancer: Diagnosis and Treatment [CG80]* (National Institute for Health and Care Excellence, 2009).
25. H. J. Thomson, S. Potter, R. J. Greenwood, et al., “A Prospective Longitudinal Study of Cosmetic Outcome in Immediate Latissimus Dorsi Breast Reconstruction and the Influence of Radiotherapy,” *Annals of Surgical Oncology* 15, no. 4 (2008): 1081–1091, <https://doi.org/10.1245/s10434-007-9772-2>.
26. Z. E. Winters, J. Haviland, V. Balta, et al., “Integration of Patient-Reported Outcome Measures With Key Clinical Outcomes After Immediate Latissimus Dorsi Breast Reconstruction and Adjuvant Treatment,” *Journal of British Surgery* 100, no. 2 (2013): 240–251, <https://doi.org/10.1002/bjs.8959>.
27. M. Barry, and M. R. Kell, “Radiotherapy and Breast Reconstruction: A Meta-Analysis,” *Breast Cancer Research and Treatment* 127, no. 1 (2011): 15–22, <https://doi.org/10.1007/s10549-011-1401-x>.
28. M. V. Schaverien, R. D. Macmillan, and S. J. McCulley, “Is Immediate Autologous Breast Reconstruction With Postoperative Radiotherapy Good Practice?: A Systematic Review of the Literature,” *Journal of Plastic, Reconstructive & Aesthetic Surgery* 66, no. 12 (2013): 1637–1651, <https://doi.org/10.1016/j.bjps.2013.06.059>.
29. J. A. Ricci, S. Epstein, A. O. Momoh, S. J. Lin, D. Singhal, and B. T. Lee, “A Meta-Analysis of Implant-Based Breast Reconstruction and Timing of Adjuvant Radiation Therapy,” *Journal of Surgical Research* 218 (2017): 108–116, <https://doi.org/10.1016/j.jss.2017.05.072>.
30. M. Wilson, M. Dordea, A. Light, M. P. Serra, and S. R. Aspinall, “Accuracy of a Multidisciplinary Team-Led Discussion in Predicting Postmastectomy Radiotherapy,” *Annals of The Royal College of Surgeons of England* 97, no. 3 (2015): 198–203, <https://doi.org/10.1308/003588414X14055925061153>.
31. E. Sewart, N. L. Turner, E. J. Conroy, et al., “The Impact of Radiotherapy on Patient-Reported Outcomes of Immediate Implant-Based Breast Reconstruction With and Without Mesh,” *Annals of Surgery* 275, no. 5 (2022): 992–1001, <https://doi.org/10.1097/SLA.0000000000004245>.
32. A. L. Pusic, E. Matros, N. Fine, et al., “Patient-Reported Outcomes 1 Year After Immediate Breast Reconstruction: Results of the Mastectomy Reconstruction Outcomes Consortium Study,” *Journal of Clinical Oncology* 35, no. 22 (2017): 2499–2506, <https://doi.org/10.1200/JCO.2016.69.9561>.
33. P. Singh, K. Hoffman, M. V. Schaverien, et al., “Neoadjuvant Radiotherapy to Facilitate Immediate Breast Reconstruction: A Systematic Review and Current Clinical Trials,” *Annals of Surgical Oncology* 26, no. 10 (2019): 3312–3320, <https://doi.org/10.1245/s10434-019-07538-x>.
34. A. Recht, E. A. Comen, R. E. Fine, et al., “Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update,” *Journal of Clinical Oncology* 34, no. 36 (2016): 4431–4442, <https://doi.org/10.1200/JCO.2016.69.1188>.
35. S. A. L. Bartels, M. Donker, C. Poncet, et al., “Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial,” *Journal of Clinical Oncology* 41, no. 12 (2023): 2159–2165, <https://doi.org/10.1200/JCO.22.01565>.
36. K. Clements, D. Dodwell, G. Lawrence, et al., “Radiotherapy After Mastectomy for Screen-Detected Ductal Carcinoma In Situ,” *European Journal of Surgical Oncology (EJSO)* 41, no. 10 (2015): 1406–1410, <https://doi.org/10.1016/j.ejso.2015.07.021>.
37. F. Cardoso, v.t. V. LJ, J. Bogaerts, et al., “70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer,” *New England Journal of Medicine* 375, no. 8 (2016): 717–729, <https://doi.org/10.1056/NEJMoa1602253>.
38. J. A. Sparano, R. J. Gray, D. F. Makower, et al., “Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer,” *New England Journal of Medicine* 379, no. 2 (2018): 111–121, <https://doi.org/10.1056/NEJMoa1804710>.
39. K. Kalinsky, W. E. Barlow, J. R. Gralow, et al., “21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer,” *New England Journal of Medicine* 385, no. 25 (2021): 2336–2347, <https://doi.org/10.1056/NEJMoa2108873>.
40. J. G. Scott, G. Sedor, P. Ellsworth, et al., “Pan-Cancer Prediction of Radiotherapy Benefit Using Genomic-Adjusted Radiation Dose (GARD): A Cohort-Based Pooled Analysis,” *Lancet Oncology* 22, no. 9 (2021): 1221–1229, [https://doi.org/10.1016/S1470-2045\(21\)00347-8](https://doi.org/10.1016/S1470-2045(21)00347-8).
41. N. Khavanin, C. S. Qiu, A. S. Mlodinow, M. M. Vu, R. G. Dorfman, and N. A. Fine, “External Validation of the Breast Reconstruction Risk Assessment Calculator,” *J Plast Reconstr Aesthet Surg.* 70 (2017): 876–883.
42. J. T. Blough, M. M. Vu, C. S. Qiu, et al., “Beyond 30 Days: A Risk Calculator for Longer Term Outcomes of Prosthetic Breast Reconstruction,” *Plastic and Reconstructive Surgery-Global Open* 6, no. 12 (2018): e2065, <https://doi.org/10.1097/GOX.0000000000002065>.
43. T. Rattay, P. Seibold, M. E. Aguado-Barrera, et al., “External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort,” *Frontiers in Oncology* 10 (2020): 575909, <https://doi.org/10.3389/fonc.2020.575909>.
44. I. Kindts, G. Defraene, S. Petillion, et al., “Validation of a Normal Tissue Complication Probability Model for Late Unfavourable Aesthetic Outcome After Breast-Conserving Therapy,” *Acta Oncologica* 58, no. 4 (2019): 448–455, <https://doi.org/10.1080/0284186X.2018.1548775>.

Supporting Information

Additional supporting information can be found online in the Supporting Information section. **Supporting Information 1.** Table S1: Further patient demographics by type of surgical procedure. Table S2: Percentages where RT is recommended by MDT (or discussed with the patient) versus not recommended, stratified by procedure type and T stage or N stage. Table S3: Adjusted odds ratios for whether RT is recommended by MDT (or discussed with the patient) versus not recommended amongst (a) those undergoing mastectomy only and (b) those undergoing any other type of breast reconstruction. **Supporting Information 2.** Figure S1: Scatter plot of implant-only reconstruction (IBR) percentages and postmastectomy radiotherapy (PMRT) recommendation percentages ($n = 2381$, excluding centres outside the UK and Ireland).